We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
From May 2019 to May 2024
By Carlo Martuscelli
GlaxoSmithKline PLC (GSK.LN) has offered unspecified concessions to address competition concerns over its proposed healthcare joint venture with Pfizer Inc. (PFE), the European Commission said Thursday.
The EU authority said it will come to a decision on the proposed combination by July 10.
The U.K. pharmaceutical company in December said it planned to create a consumer health-focused joint venture with U.S. drugmaker Pfizer, with the aim of eventually spinning it off.
The plans are being investigated by the EU's competition body to make sure that they don't breach market rules.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
June 20, 2019 06:38 ET (10:38 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
